Ogaga Urhie1, Ryan Turner2, Brandon Lucke-Wold1, Walid Radwan2, Janice Ahn3, Kymberly Gyure3, Sanjay Bhatia4. 1. West Virginia University School of Medicine, Morgantown, West Virginia, USA; Department of Neurosurgery, West Virginia University Hospitals, Morgantown, West Virginia, USA. 2. Department of Neurosurgery, West Virginia University Hospitals, Morgantown, West Virginia, USA. 3. Department of Pathology and Neurology, West Virginia University Health Sciences Campus, Morgantown, West Virginia, USA. 4. Department of Neurosurgery, West Virginia University Hospitals, Morgantown, West Virginia, USA. Electronic address: sbhatia@hsc.wvu.edu.
Abstract
BACKGROUND: Glioblastoma is a fatal brain cancer with low median and yearly survival rates. Standard of care for treating glioblastoma is gross total resection (GTR) coupled with the Stupp protocol, but various factors influence the interventions undertaken and survival achieved. As health disparities exist in rural areas, survival in these areas needs to be assessed to understand which factors detract from the successes of these standard medical interventions. METHODS: We retrospectively determined impact of age at diagnosis, number of lesions, the molecular marker O6-methylguanine methyltransferase (MGMT), extent of surgery, and completion of the Stupp protocol on survival in patients treated at West Virginia University Hospitals. We also compared our findings with a pre-Stupp protocol study done in West Virginia in 1996. RESULTS: Age <60 years at diagnosis, having the MGMT gene methylated, having a unifocal tumor, receiving GTR, adhering to the Stupp protocol, and undergoing a treatment course of GTR followed by the Stupp protocol significantly increased survival. Comparison with the 1996 study showed that although overall median survival has not increased, all interventions involving GTR have resulted in a significantly higher survival. CONCLUSIONS: We can serve our patient population by offering GTR to all adult patients with glioblastoma when no contraindications exist and ensuring that patients follow the Stupp protocol. After discharge, the Stupp protocol may not be followed or completed for a variety of reasons. In the future, we aim to assess these reasons and analyze other significant interventional and socioeconomic factors that influence survival.
BACKGROUND:Glioblastoma is a fatal brain cancer with low median and yearly survival rates. Standard of care for treating glioblastoma is gross total resection (GTR) coupled with the Stupp protocol, but various factors influence the interventions undertaken and survival achieved. As health disparities exist in rural areas, survival in these areas needs to be assessed to understand which factors detract from the successes of these standard medical interventions. METHODS: We retrospectively determined impact of age at diagnosis, number of lesions, the molecular marker O6-methylguanine methyltransferase (MGMT), extent of surgery, and completion of the Stupp protocol on survival in patients treated at West Virginia University Hospitals. We also compared our findings with a pre-Stupp protocol study done in West Virginia in 1996. RESULTS: Age <60 years at diagnosis, having the MGMT gene methylated, having a unifocal tumor, receiving GTR, adhering to the Stupp protocol, and undergoing a treatment course of GTR followed by the Stupp protocol significantly increased survival. Comparison with the 1996 study showed that although overall median survival has not increased, all interventions involving GTR have resulted in a significantly higher survival. CONCLUSIONS: We can serve our patient population by offering GTR to all adult patients with glioblastoma when no contraindications exist and ensuring that patients follow the Stupp protocol. After discharge, the Stupp protocol may not be followed or completed for a variety of reasons. In the future, we aim to assess these reasons and analyze other significant interventional and socioeconomic factors that influence survival.
Authors: Ovidiu Marina; John H Suh; Chandana A Reddy; Gene H Barnett; Michael A Vogelbaum; David M Peereboom; Glen H J Stevens; Heinrich Elinzano; Samuel T Chao Journal: J Neurosurg Date: 2011-05-06 Impact factor: 5.115
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Jörg Felsberg; Marion Rapp; Simon Loeser; Rolf Fimmers; Walter Stummer; Matthias Goeppert; Hans-Jacob Steiger; Britta Friedensdorf; Guido Reifenberger; Michael C Sabel Journal: Clin Cancer Res Date: 2009-10-27 Impact factor: 12.531
Authors: Faris Durmo; Anna Rydhög; Frederik Testud; Jimmy Lätt; Benjamin Schmitt; Anna Rydelius; Elisabet Englund; Johan Bengzon; Peter van Zijl; Linda Knutsson; Pia C Sundgren Journal: PLoS One Date: 2020-12-29 Impact factor: 3.240